NCT06610734 2026-02-09
SKY
Sichuan University
Phase 2 Recruiting
Clinical Trials
4 trialsNCT05856695 2025-09-24
TAXIO
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT07022301 2025-06-15
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
First Affiliated Hospital of Wannan Medical College
Phase 2 Not yet recruiting
NCT06429696 2025-05-28
PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting